Company Healios K.K.

Equities

4593

JP3835100003

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for Healios K.K.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Japan Exchange Other stock markets 10:30:00 2024-07-15 pm EDT			5-day change	1st Jan Change
182 ^JPY	-0.55%		+6.43%	+10.30%

Jun. 20	Healios to Book $3 Million Upfront Payment as Sales Revenue in Q2 Following License Deal with Astellas Institute	MT
Jun. 19	Healios K.K. Enters into License Agreement with Astellas Institute for Regenerative Medicine	CI

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

Number of employees: 64

JPY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	90	100.0 %	121	100.0 %	+34.44%

JPY in Million	2022	Weight	2023	Weight	Delta
United States 71.3 %	17	18.9 %	87	71.3 %	+411.76%
Japan 26.2 %	63	70.0 %	32	26.2 %	-49.21%
Others 2.5 %	10	11.1 %	3	2.5 %	-70.00%

Managers	Title	Age	Since
Hardy Kagimoto CEO	Chief Executive Officer	47	11-02-23
Richard Kincaid DFI	Director of Finance/CFO	47	18-02-28
Masanori Sawada CTO	Chief Tech/Sci/R&D Officer	43	12-03-31
Kouichi Tamura CTO	Chief Tech/Sci/R&D Officer	67	14-09-30
David W. Smith BRD	Director/Board Member	63	18-02-28
Yoshinari Matsuda BRD	Director/Board Member	45	12-12-31
Jun Narimatsu BRD	Director/Board Member	55	13-11-30

Members of the board	Title	Age	Since
Michael J. Alfant BRD	Director/Board Member	63	12-12-31
Gregory Bonfiglio BRD	Director/Board Member	72	18-02-28
Hardy Kagimoto CEO	Chief Executive Officer	47	11-02-23
Seigo Kashii BRD	Director/Board Member	70	17-02-28
Jun Narimatsu BRD	Director/Board Member	55	13-11-30
Richard Kincaid DFI	Director of Finance/CFO	47	18-02-28
Yoshinari Matsuda BRD	Director/Board Member	45	12-12-31
Kouichi Tamura CTO	Chief Tech/Sci/R&D Officer	67	14-09-30
Masanori Sawada CTO	Chief Tech/Sci/R&D Officer	43	12-03-31
David W. Smith BRD	Director/Board Member	63	18-02-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	90,130,300	56,688,622 ( 62.90 %)	278 ( 0.000308 %)	62.90 %

Name	Equities	%	Valuation
Hardy Kagimoto 31.88 %	28,730,300	31.88 %	34 M ¥
Athos Capital Ltd. 14.98 %	13,503,300	14.98 %	16 M ¥
NIKON CORPORATION 1.706 %	1,537,400	1.706 %	2 M ¥
SUMITOMO PHARMA CO., LTD. 1.664 %	1,500,000	1.664 %	2 M ¥
Oasis Management (Hong Kong) LLC 1.156 %	1,041,700	1.156 %	1 M ¥
Mirabella Financial Services LLP 1.156 %	1,041,700	1.156 %	1 M ¥
Takayuki Hasumi 0.7323 %	660,000	0.7323 %	779 559 ¥
Heights Capital Management, Inc. 0.7102 %	640,100	0.7102 %	756 054 ¥
Daisuke Yagi 0.6657 %	600,000	0.6657 %	708 690 ¥
Panview Capital Ltd. 0.6029 %	543,400	0.6029 %	641 837 ¥

Name	Equities	%	Valuation
HEALIOS K.K. 0.00%	200	0.00%	236 $

Healios KK

1-7-1 Yurakucho Chiyoda-Ku

100-0006, Tokyo

http://www.healios.co.jp

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

183 JPY

Average target price

280 JPY

Spread / Average Target

+53.01%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
HEALIOS K.K.	+10.91%	104M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	126B
ARGENX SE	+24.16%	27.95B
BIONTECH SE	-20.17%	20.5B
GENMAB A/S	-16.06%	17.12B
BEIGENE, LTD.	-18.07%	16.1B
WUXI APPTEC CO., LTD.	-47.70%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.38B
INSMED INCORPORATED	+149.98%	12.37B

Bio Therapeutic Drugs